Castle Biosciences
CSTL
157 hedge funds and large institutions have $569M invested in Castle Biosciences in 2022 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 58 increasing their positions, 46 reducing their positions, and 13 closing their positions.
44,862% more call options, than puts
Call options by funds: $5.84M | Put options by funds: $13K
85% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 13
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
26% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 46
16% more capital invested
Capital invested by funds: $491M → $569M (+$77.9M)
8% more funds holding
Funds holding: 146 → 157 (+11)
2.8% less ownership
Funds ownership: 85.91% → 83.11% (-2.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$8.35M |
| 2 |
Principal Financial Group
Des Moines,
Iowa
|
+$5.22M |
| 3 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$4.58M |
| 4 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$4.08M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$3.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$11.1M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$10.1M |
| 3 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$9.74M |
| 4 |
NAMA
Nikko Asset Management Americas
New York
|
-$9.57M |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$6.48M |
CSTL Hedge Fund Activity: Q3 2022 in Review
157 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Castle Biosciences (CSTL) for Q3 2022, worth a combined $569M — up 16% from $491M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new CSTL positions and 13 closed out — a net gain of 11 holders — while 58 added to existing stakes and 46 trimmed.
The largest buyer was Soleus Capital Management, opening a new position worth an estimated $8.35M. The largest seller was RTW Investments, cutting an estimated $11.1M.
- 157 institutional investors held Castle Biosciences (CSTL) as of Q3 2022, up from 146 in Q2 2022.
- Funds reported $569M of Castle Biosciences stock for Q3 2022, up 16% quarter-over-quarter.
- 24 funds opened new Castle Biosciences positions in Q3 2022 and 13 closed out, a net change of +11 holders.
- The largest Castle Biosciences buyer in Q3 2022 was Soleus Capital Management, an estimated $8.35M added.
- The largest Castle Biosciences seller in Q3 2022 was RTW Investments, an estimated $11.1M sold.
Based on aggregated 13F filings for Q3 2022.